Bend Article News Today

Cilta-cel is a BCMA-directed and genetically modified autologous T-cell immunotherapy that involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR), which detects

Vistagen has signed a definitive agreement for the acquisition of clinical-stage drug development firm Pherin Pharmaceuticals.

The US FDA has granted fast track designation (FTD) for Kintara Therapeutics’ REM-001, to treat cutaneous metastatic breast cancer (CMBC).

The regulatory authorities in Taiwan and South Korea have granted fast-tracked approval process for Everest Medicines’ Nefecon.

SRI and Amylyx have joined forces to develop new drug candidates to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Mogrify has collaborated with Astellas Pharma to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss.

ViGeneron, a Germany-based gene therapy company, has entered a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals.

The US Food and Drug Administration (FDA) has declined to grant approval for Gilead Sciences’ investigational therapy lenacapavir for HIV.

ViiV Healthcare has secured the US FDA approval for the expanded labelling of Cabenuva (cabotegravir, rilpivirine) to treat HIV-1 in adults.

Abbvie has submitted applications to the US FDA and the EMA to obtain approvals for upadacitinib (RINVOQ) to treat nr-axSpA.